Bone cell interactions through Eph/ephrin
Bone modeling, remodeling and associated diseases

Koichi Matsuo* and Natsuko Otaki

Laboratory of Cell and Tissue Biology; School of Medicine; Keio University; Tokyo, Japan

**Keywords:** chondrocyte, osteoblast, osteoclast, coupling factor, coupling inhibitor, cell-cell interaction, osteoarthritis, rheumatoid arthritis, multiple myeloma, osteosarcoma

Bones cannot properly form or be maintained without cell-cell interactions through ephrin ligands and Eph receptors. Cell culture analysis and evaluation of genetic mouse models and human diseases reveal various ephrins and Eph functions in the skeletal system. Migration, attachment and spreading of mesenchymal stem cells are regulated by ephrinB ligands and EphB receptors. ephrinB1 loss-of-function is associated with craniofrontonasal syndrome (CFNS) in humans and mice. In bone remodeling, ephrinB2 is postulated to act as a “coupling stimulator.” In that case, bidirectional signaling between osteoclastic ephrinB2 and osteoblastic EphB4 suppresses osteoclastic bone resorption and enhances osteoblastic bone formation, facilitating the transition between these two states. Parathyroid hormone (PTH) induces ephrinB2 in osteoblasts and enhances osteoblastic bone formation. In contrast to ephrinB2, ephrinA2 acts as a “coupling inhibitor,” since ephrinA2 reverse signaling into osteoclasts enhances osteoclastogenesis and EphA2 forward signaling into osteoblasts suppresses osteoblastic bone formation and mineralization. Furthermore, ephrins and Ephs likely modulate pathological conditions such as osteoarthritis, rheumatoid arthritis, multiple myeloma and osteosarcoma. This review focuses on ephrin/Eph-mediated cell-cell interactions in bone biology.

**Introduction**

Bone cells such as osteoblasts and osteoclasts must proliferate, migrate, attach, spread and differentiate from precursor cells originating from mesenchymal or hematopoietic stem cells. Cell-cell interaction through ephrins and Ephs regulates these processes. Analysis of animal models and human disease indicates that ephrins and Eph function in somitogenesis, craniofacial development and limb development. Once they form, bones are maintained by bone remodeling, which is also influenced by ephrins and Ephs. In addition, in bone diseases such as osteoarthritis, rheumatoid arthritis or bone-associated tumors such as multiple myeloma and osteosarcoma, signaling mediated by ephrins and Ephs likely affects disease progression.

Eph receptors belong to a subfamily of receptor tyrosine kinases activated by ligands called ephrins (Eph receptor interacting proteins). Both Ephs and ephrins are divided into two A and B groups. Generally, EphA receptors (EphA1–A8, A10) interact with ephrinA (ephrinA1–A5) and EphB receptors (EphB1–B6) interact with ephrinB ligands (ephrinB1–B3), with some exceptions. As an exception, EphA4 binds to ephrinB2 and ephrinB3 as well as to ephrinAs. From the extracellular N-terminus, Eph receptors are composed of an ephrin-binding domain, a cysteine-rich region, two fibronectin type III domains, a juxtamembrane region, a kinase domain, a sterile α motif (SAM) and a C-terminal PDZ-domain binding motif. EphA4 ligands attach to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, while ephrinB ligands are transmembrane proteins containing a conserved cytoplasmic tail and a C-terminal PDZ-domain binding motif. Eph receptors interact with ephrins at the cell surface, triggering bidirectional signaling: forward through Eph receptors and reverse through ephrins.

**Stem Cell Attachment and Migration**

Ephrin/Eph signaling reportedly mediates cancer cell migration and attachment and regulates similar migratory behavior of mesenchymal stromal/stem cells (MSCs) and dental pulp stem cells (DPSCs). MSCs contribute to skeletal tissue formation by differentiating into chondrocytes, osteoblasts, and tendon cells. When cultured human MSCs are treated with soluble EphB-Fc, MSCs become rounder and smaller, indicating that reverse signaling through ephrinB inhibits MSC attachment (Fig. 1). By contrast, treatment of MSCs with ephrinB-Fc promotes MSC migration. This activity is likely mediated by forward signaling through EphB2, as MSCs lacking EphB2 are unaffected by this treatment.

DPSCs reside in the perivascular niche of dental pulp, and their attachment and migration are dependent on ephrin/Eph...
signaling. Like human MSCs, human DPSCs treated with EphB2-Fc become rounder and smaller, although MSCs and DPSCs respond differently to certain ephrin-Fc or Eph-Fc molecules in morphological and migration assays. Since ephrinB1 gene expression is downregulated following tooth injury, ephrin/Eph signaling in DPSCs may function in tooth repair.

Somite Formation and EphA4

EphA4 signaling regulates formation of somites, which are blocks of mesodermal cells located on both sides of the notochord. Somites, which are derived from unsegmented paraxial mesoderm called presomitic mesoderm (PSM), give rise to vertebrae and ribs, muscle and other connective tissues. In fact, the ventral part of somite becomes the sclerotome and the caudal compartment of one sclerotome fuses to the rostral component of the consecutive sclerotome to form one vertebra through a process called resegmentation. Among factors that drive somite formation in early embryos, the basic helix-loop-helix transcription factor Mesp2 is crucial for defining the segmental border. Notch signaling induces Mesp2 transcription at a future somitic compartment, and Mesp2, in turn, downregulates Notch signaling in the anterior half of each presumptive segment.

In the anterior PSM cells posterior to the presumptive somite boundary, EphA4 is induced as a direct transcriptional target of Mesp2, while cells in the posterior half of presumptive segment express ephrins. Interaction between EphA4 and ephrins is required for somitogenic boundary formation (Fig. 1). Consistently, ectopic Mesp2 expression induces EphA4 and leads to skeletal malformation. Similarly, forced expression of cMeso-1, the chicken homolog of mouse Mesp2, in chick embryos results in ectopic boundary formation in the PSM. Of genes downstream of cMeso-1, only EphA4 is required for somitic boundary formation. Nonetheless, severe skeletal phenotypes have not been reported in EphA4 knockout mice, presumably due to EphA receptor redundancy.

Craniofacial Development and EphrinB1

In humans, ephrinB1 is encoded by the X-linked EFNB1 gene, and EFNB1 mutations are associated with craniofrontonasal syndrome (CFNS). Unlike other X-linked disorders, females are more severely affected than males (see below). CFNS is characterized by cleft palate, hypertelorism, frontonasal dysplasia, agenesis of the corpus callosum, hypoplasia of the maxilla and other anomalies of neurological and skeletal development (Fig. 1). Mice lacking ephrinB1 generated by crossing Efnb1 floxed mice with a line ubiquitously expressing Cre recombinase (Pgk-Cre) exhibit multiple skeletal malformations.

In mice, proliferation of palatal mesenchyme cells controls palatal shelf outgrowth initiated from the invaginated surface of the maxillary processes beginning around embryonic day 11.5 (E11.5). The palatal shelves are vertically positioned lateral to the tongue by E13.5 and then are elevated to a horizontal position, grow and fuse. ephrinB1 is required for this elevation and the PDZ target site of ephrinB1 is crucial for that activity. Forward signaling through EphB2 (previously called Nuk) and EphB3 (previously called Sek4) cooperate in palate formation.
Why are female CFNS patients more severely affected than males? In female ephrinB1 heterozygous mutants, X inactivation generates ephrin-B1-expressing and -non-expressing cells, and these two populations of cells segregate via “homophilic sorting,” causing abnormal tissue boundaries in calvaria, palate and other tissues.\textsuperscript{21,22} This homophilic sorting process, termed “cellular interference,”\textsuperscript{23} cannot occur in males. Inhibition of gap junction communication at ectopic ephrin/Eph boundaries may underlie CFNS.\textsuperscript{24}

Osteoblast-specific conditional ephrinB1 knockout (KO) mice created using collagen α2 (I) promoter-Cre transgene show exencephaly due to reduced size of calvarial bones such as frontal, parietal and interparietal bones in both mutant hemizygous males and homozygous females,\textsuperscript{25} in contrast to ubiquitous ephrinB1 KO mice, which show skull defects exclusively in heterozygous females.\textsuperscript{26} Long bones of mice harboring conditional KO ephrinB1 in osteoblasts are also reduced in size and bone mineral density. Consistently, in vitro gain-of-function experiments of ephrinB1 suggest that ephrinB1 reverse signaling dephosphorylates TAZ (a transcriptional coactivator with a PDZ binding motif) within a protein complex, releasing TAZ from the complex to translocate into nucleus and to induce expression of osteoblast-specific transcription factor osterix, osteoblastic differentiation and mineralization.\textsuperscript{25}

**Limb Development and Polydactyly**

Besides craniofacial phenotypes, heterozygous female ephrinB1 KO mice show polydactyly restricted to digits I or II in forelimbs or hindlimbs.\textsuperscript{26} Although sonic hedgehog (Shh) and homeobox A13 (Hoxa13) are implicated in polydactyly, their expression is not altered in the absence of ephrinB1.\textsuperscript{26} Curiously, expression of EphA7 (ephrinA5 is a cognate ligand) is markedly reduced in affected digits of Hoxa13 mutant mice and in mutant mesenchymal cells together with loss of chondrogenic capacity.\textsuperscript{27} Ectopic EphA4 expression in limb buds of ephrinB1 heterozygous female mice at E12.5 is associated with the presence of an excess number of mesenchymal condensations.\textsuperscript{26} EphA4 expression is also altered in the polydactyloous talpid\textsuperscript{e} mutant in the chick.\textsuperscript{28} These data suggest that multiple ephrin/Eph family members including ephrinB1, EphA4 and EphA7 contribute to patterning of digits.

**Bone Cells**

Bone cells such as chondrocytes, osteoblasts, osteocytes and osteoclasts express a subset of ephrin ligands and Eph receptors. Chondrocytes and osteoclasts are of mesenchymal origin. Osteoblasts differentiate through activation of Runx-related transcription factor 2 (Runx2, also called Cbfα1) and osterix and secrete extracellular matrix proteins.\textsuperscript{29} A population of osteoblasts becomes embedded in bone matrix and terminally differentiates into osteocytes, which communicate with each other through gap junctions at the tips of dendrites extending into osteocytic canaliculi.\textsuperscript{30} Osteoclasts are specialized macrophages of hematopoietic origin that resorb bone.\textsuperscript{31} Osteoblasts and osteocytes express the receptor activator of NFκB ligand (RANKL), which, together with macrophage-colony stimulating factor (M-CSF), induces osteoclastic differentiation through activation of the transcription factors c-Fos (encoded by Fos) and nuclear factor of activated T-cells c1 (NFATc1) in macrophagic precursors.\textsuperscript{32,33} These mononuclear precursor cells fuse to form multinucleated osteoclasts. In addition to bone cells, endothelial cells and neurons in bones and in the bone marrow also express ephrins and Ephs. Therefore, diverse cell-cell interactions mediated by ephrins and Ephs occur in bone.\textsuperscript{34}

**Expression of Ephrins and Ephs in Bone Cells**

Eph receptors and ephrin ligands are also found in chondrocytes, osteoclasts and osteoblasts and osteocytes. EphA4 is expressed in mouse growth plate cartilage, and its expression increases during endochondral ossification. EphA4 is also expressed in human chondrocytic cell lines.\textsuperscript{35} Human articular cartilage cells express ephrinB2 and EphB4.\textsuperscript{36} During differentiation of cultured osteoclasts induced by RANKL, ephrinA2, B1 and B2, and receptors EphA1, A2, A4 are dynamically expressed as revealed by RT-PCR (Fig. 2).\textsuperscript{37,38} Since expression of EphB receptors is not detectable in osteoclasts, ephrinB1 and B2 expressed on osteoclasts likely stimulate EphB receptors on non-osteoclastic cells such as osteoblasts. Cells in osteoblast cultures express most ephrinAs, ephrinBs, EphAs and EphB2, and their expression levels are generally uniform (Fig. 2).\textsuperscript{37,38,40} Osteocytes also express ephrins and Ephs (see below).

**Endochondral Ossification and Ephrin/Eph**

Several flat bones including calvarial bone form through the process of membranous ossification. Other bones, such as basal skull, long bones and vertebrae form through endochondral ossification.\textsuperscript{29} During development, mesenchymal cells condense and differentiate into chondrocytes to form avascular cartilage models of future bones. Chondrocytes within cartilage terminally differentiate into hypertrophic chondrocytes, which produce vascular endothelial growth factor (VEGF) to stimulate angiogenesis. In the vasculature, ephrinB2 is expressed in arterial endothelial cells, while one of its cognate receptors, EphB4, is predominantly expressed in venous endothelial cells.\textsuperscript{41} Although formation of the primary blood capillary plexus reportedly requires signaling mediated by ephrinB2 and its Eph receptors,\textsuperscript{32-34} it is unclear whether ephrinB2 functions in the blood capillary invasion into hypertrophic chondrocytes at the growth plate.

Concomitant with capillary invasion, osteoclast and osteoblast precursors enter into cartilage and replace it with bone.\textsuperscript{45} Since atrial endothelial cells express ephrinB2 on their luminal side,\textsuperscript{46,47} interaction between ephrinB2-expressing endothelial cells and EphB-receptor-expressing monocytes\textsuperscript{47} or MSCs/osteoblast precursors likely promotes adhesion and transmigration of these cells, which may serve as a mechanism to deliver osteoclast and osteoblast precursors to hypertrophic chondrocytes, where they are exposed to respective differentiation cues including RANKL\textsuperscript{48,49} and bone morphogenetic proteins (BMPs). Curiously, ephrinB2 controls VEGF-induced angiogenesis\textsuperscript{50,51} and osteoclasts express ephrinB2.\textsuperscript{57} Thus it is tempting
Bidirectional Osteoclast-Osteoblast Communication

Mice lacking the transcription factor c-Fos (Fos) lack osteoclasts and develop osteopetrosis. These mice also fail to express other Fos family proteins, Fra-1, Fra-2 and FosB, in osteoclast lineage cells, and overexpression of any Fos protein in For−/− hematopoietic precursors rescues osteoclastogenesis. Expression of Fos family proteins is essential to induce expression of the transcription factor NFATc1, the master regulator of osteoclast differentiation, which rescues osteoclastogenesis of For−/− hematopoietic precursors. Several osteoclast-specific genes including tartrate-resistant acid phosphatase (TRAP, Acp5), cathepsin K (Csk), chloride channel 7 (Clcn7) and matrix metalloproteinase 9 (Mmp9) are transcriptional targets of NFATc1. EphrinB2 was identified as an NFATc1 target gene in microarray screening for genes upregulated following expression of a constitutively active form of an NFAT protein in For−/− hematopoietic precursors cultured in the presence of RANKL and M-CSF. Both ephrinB2 mRNA and protein are significantly upregulated during osteoclastogenesis in vitro, and immunohistochemistry indicates high ephrinB2 expression in TRAP-positive osteoclasts in vivo. Addition of EphB4-Fc to osteoclastogenic cultures to stimulate reverse signaling suppresses osteoclast differentiation via suppression of Fos and therefore Nfatc1 transcription, while cultured hematopoietic precursors lacking ephrinB2 differentiate more efficiently than do wild-type controls. Therefore, ephrinB2 is a negative regulator of bone resorption (Fig. 3). The ephrinB2 C-terminal PDZ interaction site is indispensable for suppression of osteoclast differentiation. A requirement for ephrinB2 interaction with PDZ domain effectors has also been reported for lymphatic development. Dishevelled 2 (Dvl2) is a candidate PDZ domain effector that interacts with ephrinB2 during osteoclast differentiation.

Conditional KO mice with myeloid lineage-specific deletion of ephrinB1 (Efnb1LysMcreLysMcKO) show increased osteoclast formation and reduced bone mass, indicating that ephrinB1 in osteoclasts negatively regulates bone resorption as does ephrinB2. Similar conditional ephrinB2 KO mice generated using the same LysMcre mice do not show reduced bone mass, suggesting that ephrinB1 can compensate ephrinB2 functions, but not vice versa.

Forward signaling through EphB4 into osteoblasts enhances osteoclast differentiation both in osteoblastogenic cultures and in α1(I) collagen promoter-EphB4 transgenic mice via inhibition of the small GTPase RhoA. Therefore, bidirectional signaling between osteoclasts and osteoblasts is likely mediated by ephrinB1/B2 and EphB receptors including EphB4 (Fig. 3). On the other hand, osteoblasts also upregulate ephrinB2 in response to parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHRP) signaling, and blockade of ephrinB2/EphB4 interaction in osteoblasts inhibits mineralization. In mice lacking the cytoplasmic adaptor protein β-arrestin2, PTH significantly downregulates expression of ephrins B1 and B2 and Eph B2, B3, B4, A3 and A4 relative to levels seen in wild-type mice, consistent with enhanced PTH-stimulated osteoclastogenesis seen in these KO mice.

Figure 2. Expression of ephrins and Eps during bone cell differentiation. (A) Osteoclast differentiation is induced by RANKL and M-CSF in vitro and then ephrin/Eph mRNA expression is monitored on the days indicated. (B) Osteoblast differentiation is induced by ascorbic acid and β-glycerophosphate in vitro and ephrin/Eph mRNA expression was similarly analyzed. Bar height represents changes in relative expression levels of each gene, based mainly on RT-PCR data. Levels can be compared only within a gene, not across genes. ephrin and Eph names in bold are discussed in detail in this review. Asterisks (*) indicate that mRNA expression levels are accompanied by corresponding changes in protein expression.
body and microscopic levels. Using a radioisotopic technique, investigators observed a positive correlation or "coupling" between whole body rates of bone resorption and formation. Microscopic examination showed sequential bone remodeling in which bone resorption was followed by an equivalent amount of bone formation at each basic multicellular unit (BMU). "Coupling factors" have been defined as osteoclast-derived molecules that induce osteoblastic bone formation at the BMU level by either recruiting osteoprogenitors and osteoblasts or promoting their differentiation and activation. Proposed coupling factors, such as transforming growth factor β (TGF-β) and insulin-like growth factor-1 (IGF-1), are released from the extracellular matrix by bone resorption, while factors such as cardiotrophin-1, sphingosine-1-phosphate, BMP6 and Wnt10b are secreted from osteoclasts. By contrast, ephrinB1 and ephrinB2 are membrane-bound and must function locally, unless released by shedding, to facilitate transition from bone resorption to bone formation phase at the BMU. In rat alveolar bone remodeling models, Baron and colleagues demonstrated that mononuclear phagocytic cells occupy resorption lacunae (the reversal phase) for 2.5 to 4 d between resorption and formation. These mononuclear cells are "bone lining cells" that remove collagen left by osteoclasts in resorption lacunae. Both bone lining cells and EphB4-positive pre-osteoblasts can directly interact with osteoclasts, allowing potential osteoblastic activation through ephrinB/EphB4. Since osteoclasts produce factors that not only stimulate but inhibit coupling, the above-mentioned factors may be considered "coupling inhibitors" (Fig. 4).

EphrinA2 as a "Coupling Inhibitor"

Osteoclast-derived factors also negatively regulate osteoblasts and antagonize coupling. Osteoclast-derived ephrinA2, which is expressed early during osteoclastogenesis (Fig. 2), may be such a negative regulator. In addition to ephrinA2 anchored on osteoclast membranes, soluble ephrinA2 (and ephrinB2) generated by proteolytic cleavage (ectodomain shedding) may act at a distance on osteoblasts. In osteoblastogenic cultures, forward signaling through the EphA2 receptor expressed on osteoblasts inhibit both differentiation via activation of RhoA, and mineralization (Irie et al., our unpublished data). We propose that ephrinA2 and other osteoclast-afferent factors that negatively regulate bone formation be designated "coupling inhibitors" (Fig. 4). Furthermore, reverse signaling through ephrinA2 into osteoclasts enhances osteoclastogenesis most likely via phospholipase C activation (Fig. 3). In addition to osteoclast-osteoblast interactions, osteoclast-osteoclast or osteoblast-osteoblast interactions through ephrinA2 and EphA2 can also occur (Fig. 2).

Coupling inhibitors other than ephrinA2 have been identified. Semaphorin 4D, an axon guidance molecule, is expressed in osteoblasts and binds to its receptor, Plexin-B1, in osteoblasts. This interaction suppresses bone formation through activation of RhoA. Mice lacking BMP receptor type1A (Bmpr1a) specifically in osteoclasts show enhanced bone formation, suggesting that BMP receptor signaling in osteoclasts suppresses bone formation perhaps through production of a coupling inhibitor that interacts with osteoblasts.

Arthritis and Ephrin/Eph

Osteoarthritis (OA) is a common condition that affects joints, causing pain and stiffness, cartilage degradation and synovial membrane inflammation. Cartilage pathologies may be associated with changes in subchondral bone. A subpopulation of osteoblasts derived from a human OA patients produces low levels of prostaglandin E2 (PGE2) upregulation of EphB4 by PGE2 and interleukin (IL)-17, Moreover, osteoclastogenic activity of OA-derived osteoblasts is reduced by stimulating EphB4 forward signaling by ephrinB2. In vivo studies are necessary to determine whether manipulation of ephrins/Ephs alters OA progression. In addition, treatment of human OA chondrocytes with ephrinB2 inhibits expression of IL-1β, IL-6, matrix metalloproteinase-1 (MMP1), MMP9 and MMP13, among other catabolic factors, suggesting that ephrinB2 treatment may increase anabolic activity.

Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that affects joints and many other tissues and organs. Kitamura et al. reported that ephrinB1 expression is significantly higher in synovial fibroblasts and exudate lymphocytes in patients with RA compared with those in OA. They also showed that a recombinant ephrinB1-Fc protein stimulates enhanced migration of normal peripheral blood lymphocytes, increases their TNF-α
production, and induces RA synovial cells to produce IL-6.78 High expression of ephrinBs and EphB kinases might be correlated with RA pathogenesis.79

**Bone-Related Tumors and Ephrin/Eph**

Multiple myeloma (MM) is a plasma cell malignancy often accompanied by bone osteolytic lesions.80,81 MM patients suffer pain, fractures and hypercalcemia. Osteoclastic bone resorption is elevated but osteoblastic bone formation is suppressed in MM patients, leading to osteolytic lesions. Pennisi et al. reported that ephrinB2/EphB4 expression in myelomatous bones is reduced.82 Myeloma cells suppress osteoblast differentiation by secreting Wnt signaling inhibitors such as dickkopf 1 (DKK1), sclerostin and soluble frizzled receptor-like proteins (sFRPs),83-85 as well as BMP2 signaling inhibitors, such activin A.86 Since EphB4 is a target of Wnt signaling in some tumors,87 decreased Wnt signaling in myeloma bone may suppress osteoblast differentiation, at least in part, by reducing EphB4 expression.

Osteosarcoma is a malignant bone tumor that usually develops in adolescence as rapid growth occurs. Genome-wide microarray analysis of patient osteosarcoma samples has revealed increased expression of the EPHA2 receptor and its ligand EFNA1.88 Other studies suggest that EFNB1 expression by osteosarcoma cells is a marker of poor prognosis.89 A staining pattern indicative of cytoplasmic ephrinA4 in primary osteosarcoma is associated with both progression and poor prognosis, while cytoplasmic and nuclear staining is associated with favorable prognosis.90 However, the roles of these ephrins and Ephs in osteosarcoma development and dissemination are as yet undefined. Curiously, ephrinA5 is down-regulated in chondrosarcomas compared with normal cartilage.91

**Concluding Remarks**

In this review, we have discussed ephrins and Ephs expressed in bone cells, in particular, osteoclasts, osteoblasts and bone-associated tumor cells. Although little is known about function of ephrins and Ephs in osteocytes, these abundant bone cells do express ephrins/Ephs such as ephrinB1, ephrinB2 and EphB4,6,40,77 and blockade of ephrinB2/EphB4 interaction results in decreased expression of sclerostin, a potent inhibitor of osteoblastogenesis.92 Therefore, osteocytes may communicate bidirectionally with osteoclasts or osteoblasts in response to various stimuli through ephrins/Ephs. Moreover, ephrin/Eph interaction in non-skeletal organs might contribute to bone phenotypes, given the connection of bone with organs such as kidney, brain and gut.93 Bidirectional exchange of findings relevant to ephrins and Ephs between multiple fields could shed new light on common mechanisms governing modeling and remodeling of tissues.

**Acknowledgments**

We thank Yumiko Saga, Yoshiko Takahashi, Naoko Irie, Yasunari Takada, Yukiko Kuroda and Elise Lamar for valuable comments. This work was supported by KAKENHI (21390425).
References

1. Pasqualle EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133:38-52; PMID:18393988; http://dx.doi.org/10.1016/j.cell.2008.03.011.

2. Prulèscu ME, Adams RH. Eph-ephrin molecules—a hub for signaling and endocytosis. Genes Dev 2010; 24:2480-92; PMID:21078817; http://dx.doi.org/10.1101/gad.197391.0.

3. Figa J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 2007; 17:230-8; PMID:17420216; http://dx.doi.org/10.1016/j.tcb.2007.03.004.

4. Davy A, Soriano P. Ephrin signaling in vivo: look both ways. Dev Dyn 2005; 232:1-10; PMID:15580616; http://dx.doi.org/10.1002/dvdy.20200.

5. Pasqualle EB. Eph receptors and ephrins in cancer: bidirectional signallling and beyond. Nat Rev Cancer 2010; 10:165-80; PMID:20719773; http://dx.doi.org/10.1038/nrc2808.

6. Arthur A, Zannettino A, Panagopoulos R, Kolbar SA, Sims NA, Stylianou C, et al. EphB2/ephrinB2 interaction mediates human MSC attachment, migration and osteochondral differentiation. Bone 2011; 48:533-42; PMID:21597068; http://dx.doi.org/10.1016/j.bone.2010.10.024.

7. Stokowski A, Shi S, Sun T, Bartold PM, Kolbar SA, Gronthos S. EphB2/ephrinB2 interaction mediates adult stem cell stemness, spreading, and migration: implications for dental tissue repair. Stem Cells 2007; 25:156-64; PMID:17204606; http://dx.doi.org/10.1634/memcells.2006-0573.

8. Chal J, Pourqué O. Patterning and Differentiation of the Vertebrate Spine. In: Pourquié O, ed. The Skeletal System. New York: Cold Spring Harbor Laboratory Press, 2009; 131-6.

9. Yashiko H, Haraguchi S, Kirijsma J, Takahashi Y, Kanno Y. Sla-mediated Notch signaling controls somite-specific Mesp2 expression. Proc Natl Acad Sci U S A 2006; 103:3651-6; PMID:16505880; http://dx.doi.org/10.1073/pnas.0508231103.

10. Morimoto M, Takahashi Y, Endo M, Saga Y. The Mesp2 transcription factor establishes segmental borders by suppressing Notch activity. Nature 2005; 435:354-9; PMID:15902259; http://dx.doi.org/10.1038/nature05992.

11. Nakajima Y, Morimoto M, Takahashi Y, Koeki H, Saga Y. Identification of EphA4 enhancer required for segmental expression and the regulation by Mesp2. Development 2006; 133:2517-25; PMID:16728472; http://dx.doi.org/10.1242/dev.02422.

12. Barros A, Poole RJ, Darbon L, Breton N, Holder DJ, et al. EphB2/ephrin-B2 signaling regulates the mesenchymal-epithelial transition of the paraxial mesoderm during somite morphogenesis. Curr Biol 2003; 13:1571-82; PMID:12678588; http://dx.doi.org/10.1016/j.cub.2003.08.030.

13. Watanabe T, Sato Y, Saito D, Todokoro R, Takahashi Y. EphrinB2 coordinates the formation of a morphological boundary and cell epithelialization during somite segmentation. Proc Natl Acad Sci U S A 2005; 102:7667-72; PMID:15938072; http://dx.doi.org/10.1073/pnas.0902859106.

14. Kullander K, Matheir NK, Diella F, Dottori M, Boyd AW, Klein R. Kinase-dependent and kinase-independent functions of EphA4 receptors in major axon tract formation in vivo. Neuron 2001; 29:73-84; PMID:11480827; http://dx.doi.org/10.1016/S0896-6756(01)00181-7.

15. Twigg SR, Kan R, Babbs C, Bochuva EG, Robertson SP, Wall SA, et al. Mutations of ephrin-B1 (EFPNI), a marker of tissue boundary formation, cause craniofacial syndromes. Proc Natl Acad Sci U S A 2004; 101:8652-7; PMID:15166289; http://dx.doi.org/10.1073/pnas.0402819101.
56. Martin TJ, Sims NA, Quinn JMW. Interactions among osteoblasts, osteoclasts, and other cells in bone. In: Lorenzo J, Choi Y, Horowitz M, Takayani H, eds. Osteoimmunology: Interactions of the immune and skeletal systems. Elsevier; 2011:227-27.

57. Harris WH. Osteoclast activation. Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008; 19:444-51; PMID:18718546; http://dx.doi.org/10.1016/j.semcdb.2008.07.016.

58. Heringk K, Neumann-Wulf AV, Bonewald LF, Kandul MA. Localization of coupling and bone control bone remodeling. Bone 2009; 44:1026-33; PMID:19345750; http://dx.doi.org/10.1016/j.bone.2009.03.071.

59. Walker EC, McGregor NE, Poulton IJ, Pompeolo S, Allan EH, Quinn JM, et al. Cardiac osteopontin-1 is a osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res 2008; 23:2025-32; PMID:18657589; http://dx.doi.org/10.1359/jbmr.071016.

60. Pederson L, Ruan M, Westerendt JF, Khosla S, Ouderk MJ. Regulation of bone formation by osteoblasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci U S A 2008; 105:20764-9; PMID:19057223; http://dx.doi.org/10.1073/pnas.0800765105.

61. Tang Y, Wu X, Lei W, Pang L, Wang C, Shi Z, et al. TGFB1-induced bone mesenchymal stem cells couples bone resorption with formation. Nature 2011; 515:757-65; PMID:19584867; http://dx.doi.org/10.1038/nature11983.

62. Guaquil VH, Swendamen S, Zhou W, Guaquil P, Weskamp G, Bartsch JW, et al. ADAM8 is a negative regulator of retinal neo-vascularization and of the growth of heterotopically injected tumor cells in mice. J Mol Med (Berl) 2010; 88:497-505; PMID:20117908; http://dx.doi.org/10.1002/jm.20537.

63. Mundy GR, Eleftheriou F. Bone biology: intact bone. Annu Rev Cell Dev Biol 1999; 15:120-48; PMID:10345633; http://dx.doi.org/10.1146/annurev.cellbio.15.1.120.

64. Tran Van PT, Vignery A, Baron R. Cellular kinetics of the bone remodeling sequence in the rat. Anat Rec 2002; 240:445-51; PMID:12073827; http://dx.doi.org/10.1002/ar.1092024040.

65. Vignery A, Baron R. Dynamic histomorphometry of alveolar bone remodeling in the adult rat. Anat Rec 1989; 229:191-200; PMID:2176694; http://dx.doi.org/10.1002/ar.105229174.

66. Everts V, Delaiss JM, Korper W, Jansen DC, Tielhebaart-Gutter W, Safir P, et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 2002; 17:77-80; PMID:11577162; http://dx.doi.org/10.1359/jbmr.2002.17.1.77.

67. Luiz da Freitas PH, Li M, Nominoya T, Nakamura M, Uibaudi S, Oda K, et al. Interleukin PTH administration stimulates pre-osteoblastic proliferation without leading to enhanced bone formation in osteoclast-less c-fos mice. J Bone Miner Res 2009; 24:1586-97; PMID:19419301; http://dx.doi.org/10.1359/jbmr.090413.

68. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008; 473:201-9; PMID:18466338; http://dx.doi.org/10.1016/j.jbc.2008.03.017.

69. Negishi-Koga T, Shimohara M, Komatsu N, Bito H, Kodama T, Friedel RH, et al. Suppression of bone formation by osteoclastic expression of sephamphorin 4D. Nat Med 2011; 17:1473-80; PMID:22019888; http://dx.doi.org/10.1038/nm.2489.

60. Okamoro M, Muto M, Imai Y, Ikegami D, Kamiya N, Kato S, et al. Conditional deletion of Bmp2 and in differen- tiated osteoclasts increases osteoblastic bone forma- tion, increasing volume of remodeling bone in mice. J Bone Miner Res 2011; 26:2511-22; PMID:21786321; http://dx.doi.org/10.1359/jbmr.011014.

61. Kumar SR, Schenker ES, Neale DL, Krasnopeorov V, Liu B, et al. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progress- ion. Cancer Res 2009; 69:3736-45; PMID:19366806; http://dx.doi.org/10.1158/0008-5472.CAN-08-3232.

62. Fritsch-Guenter R, Noke A, Ungethüm U, Kuhn RJ, Schlag PM, Tinn P, et al. De novo expression of EphA2 in osteosarcoma mediates survival of the mitogenic signaling pathway. Histopathology 2010; 57:836-50; PMID:21166608; http://dx.doi.org/10.1111/j.1365-2559.2010.03713.x.

---

Please note that this text is a transcription of the content from the provided image and does not contain any additional analysis or interpretation.
89. Varelias A, Kohlar SA, Cowled PA, Carter CD, Clayer M. Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis. Cancer 2002; 95:862-9; PMID:12209731; http://dx.doi.org/10.1002/cncr.10749.
90. Abdou AG, Abd el-Wahed MM, Asaad NY, Samaka RM, Abdallah R. Ephrin A4 expression in osteosarcoma, impact on prognosis, and patient outcome. Indian J Cancer 2010; 47:46-52; PMID:20071790; http://dx.doi.org/10.4103/0019-509X.58859.
91. Kalinski T, Röpke A, Sel S, Kouznetsova I, Röpke M, Roestner A. Down-regulation of ephrin-A5, a gene product of normal cartilage, in chondrosarcoma. Hum Pathol. 2009; 40:1679-85; PMID: 19695673; http://dx.doi.org/10.1016/j.humpath.2009.03.024.
92. Martin TJ, Allan EH, Ho PW, Goos JH, Quinn JM, Gillespie MT, et al. Communication between ephrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol 2010; 658:51-60; PMID:19950015; http://dx.doi.org/10.1007/978-1-4419-1050-9_6.
93. Karsenty G, Ferron M. The contribution of bone to whole-organism physiology. Nature 2012; 481:314-20; PMID:22258610; http://dx.doi.org/10.1038/nature10763.